Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Decreases By 37.4%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 313,600 shares, a decrease of 37.4% from the February 13th total of 500,700 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average daily volume of 3,190,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the specialty pharmaceutical company’s stock after acquiring an additional 18,271 shares during the quarter. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. 15.51% of the stock is owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Price Performance

Shares of Cumberland Pharmaceuticals stock traded down $0.03 during trading on Friday, reaching $5.46. The company’s stock had a trading volume of 45,268 shares, compared to its average volume of 858,952. The business has a 50 day moving average price of $4.07 and a 200-day moving average price of $2.37. Cumberland Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $7.25. The company has a market capitalization of $76.67 million, a P/E ratio of -7.09 and a beta of -0.19. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The company had revenue of $10.44 million for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 6th.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.